Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Europe Infrastructure UCITS ETF 17.08.2026 FTEI.LN IE000TIZ5AP4  300,002.00 EUR   6,531,444.88   21.771  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 17.08.2026 QDEC.LN IE000GAKWFA7  550,002.00 USD  13,600,557.82   24.728  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF- June 17.08.2026 MJUN LN IE000CO3P697  250,002.00 USD   6,403,385.20   25.613  ...
-

Options Announces CIX Trading, Canada’s Newest Alternative Trading System (ATS)

LONDON & TORONTO & HONG KONG--(BUSINESS WIRE)--Options Technology, the leading provider of trading infrastructure to the global financial markets, today announced that it will be offering CIX Trading, Canada’s newest alternative trading system (ATS), designed to modernize Canada’s Equities Markets. CIX Trading is the first ATS to go live in Canada in over 10 years, seeking to close the innovation gap between Canadian and US equity trading markets with features including extended market hours an...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Artificial Intelligence UCITS ETF 17.08.2026 FTAI IE000YIQZ0H6  225,002.00 USD   7,029,180.20   31.241  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100® Moderate Buffer UCITS ETF - March 17.08.2026 QMAR.LN IE0006S0EBF2   50,002.00 USD   1,261,908.35   25.237  ...
-

Uptiq Expands U.S. Banking Leadership as Institutions Move AI From Pilot to Production

AUSTIN, Texas--(BUSINESS WIRE)--Uptiq, the bank-grade AI platform for financial institutions, today announced senior appointments to its banking leadership team as demand from banks and credit unions accelerates to move AI out of pilots and into production. Financial regulators require explainability, audit readiness, and human oversight in decisions made by agents, requirements that general-purpose AI tools were never designed to satisfy. Gagan Kanjlia joins as Chief Banking Officer. Amit Parm...
-

With AWS Hackathon Win, TASKING-Led Team Demonstrates the Future of Automotive Safety-Critical Software Development

MUNICH--(BUSINESS WIRE)--A cross-organizational team bringing together expertise from TASKING, Infineon and the German Aerospace Center (DLR) earned the top award at the AWS “Accelerating the V-Cycle with Agentic AI” hackathon for demonstrating a governed AI-assisted engineering workflow that reimagines software-defined vehicle development. The working prototype received the competition's highest score for OEM purchase readiness, validating a new approach to connecting trusted semiconductor pro...
-

Former President of DePuy Synthes U.S. Joins Peptilogics Board

PITTSBURGH--(BUSINESS WIRE)--Tim Czartoski, orthopedic executive and former president of DePuy Synthes U.S. and most recently president of U.S. Surgical and Global R&D at Enovis, has joined the Peptilogics board of directors. His background in leading large orthopedic device businesses, including successful launches of robotic technology platforms and one of the industry’s most advanced knee systems, lends significant value to Peptilogics as it moves towards bringing meaningful innovation t...
-

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) sur...